SOPHiA GENETICS
Buying intent
39 tracked signals | Top 15 topics are below | Sales and Operations are carrying most of it.
Attention by team
LinkedIn activity, by teamWhere SOPHiA GENETICS's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.
Topics being researched
30-day windowEvery tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.
4d ago
5d ago
5d ago
9d ago
15d ago
9d ago
4d ago
23d ago
26d ago
4d ago
26d ago
10d ago
26d ago
5d ago
17d ago
Need intent for a specific topic or industry?
We track the full taxonomy across every account in the graph — including themes not shown on this page.
Who's active at SOPHiA GENETICS
verified title on fileTitles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.
See everyone, not just the first 10
11 people across every department at SOPHiA GENETICS, plus a LinkedIn profile link for each.
Primary products / business lines
LinkedIn company profileSOPHiA GENETICS was founded in 2011 by biologists who had a vision to create a technology that could make a positive and lasting impact on the world, using data for good. We’ve built a revolutionary technology platform, SOPHiA DDM™, that rapidly distills complex data into actionable insights, enabling clinicians, researchers, and biopharma to reshape the way that we diagnose and treat cancer an
Top accounts researching SOPHiA GENETICS
names withheld on the public pageThese are companies whose own people brought up SOPHiA GENETICS unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.
129,094 companies · 649,540 people are researching Artificial Intelligence
SOPHiA GENETICS's own team shows 5 signals on this topic. No one outside SOPHiA GENETICS has been seen researching the company by name yet — so this is the market it sits in, not a list of its buyers.
- Hiring66,174 cos · 318,882 people
- Precision Medicine1,145 cos · 3,537 people
Buyer profile
company size · seniorityCompany size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.
Buying committee functions
Employee job titles (LinkedIn)Sales — 4 people; Marketing — 1 person; IT — 1 person; HR / Talent — 1 person; Leadership — 1 person
What's been said
public posts mentioning SOPHiA GENETICSUp to 9 public excerpts naming SOPHiA GENETICS from the past 365 days, across LinkedIn, Reddit, X, YouTube and other public sources.
Blood-based comprehensive genomic profiling tests using circulating tumor DNA have been approved in Japan , but that’s just the starting line. Timing of use, reimbursement pathways, and clinical integration remain genuinely complex questions. The real strategic imperative is building testing capacity within Japan itself — moving away from overseas laboratory dependency. Getting turnaround times competitive, reimbursement aligned, and clinical workflows embedded locally is what actually matters for patients. Join our talk with Philippe Menu , SOPHiA GENETICS , and Michel Mommejat , A.D.A.M. Innovations (formerly Genesis Healthcare – GeneLife) as we explore how to translate the global vision of liquid biopsy into the local realities that matter in Japan. If you’re attending, let’s connect. Always better to share insights over coffee than slides.
May 2026Big steps forward for PGx in Italy! 🇮🇹 Personalized medicine shouldn’t be a privilege. It should be the standard. At SOPHiA GENETICS, we are committed to providing the AI-driven tools needed to make equitable, nationwide pharmacogenomic testing a reality. Proud of Fiammetta Biagiarelli and the team for representing our mission at the Italian Senate and Matteo Floris , Erika Cecchin , Matteo Curtarello and the scientific community in shaping this roadmap. 👏 #PGx #DigitalHealth #Innovation #Italy
Apr 2026#6 in Leading AI Companies in Genomics, and our two partners are at #1 and #2. When we say “The AI platform for Precision Medicine”, we mean it! It’s our mission, and with our customers we’re building a collective intelligence to improve patient care around the world. SOPHiA GENETICS
Apr 2026📄 New publication: The largest real-world HRD testing study in ovarian cancer to date. Rojo et al. tested decentralized genomic profiling for homologous recombination deficiency (HRD) in 4,777 ovarian carcinoma patients across 192 Spanish centers, using the SOPHiA Genetics DDM HRD Solution assay. Key findings: • ~39% of tumors were HRD-positive consistent with the 38% rate observed with the centralized assay • Strong concordance between the two platforms, supporting local laboratory implementation • Results were all delivered to clinicians in under 21 working days • HRD-positive patients showed significantly longer progression-free survival This study reinforces that decentralized HRD testing can be analytically robust and clinically meaningful - a critical step toward broader access to precision oncology for ovarian cancer patients. 🔗 https://lnkd.in/e7-Rk92i #OvarianCancer #HRD #PrecisionOncology #Genomics #Pathology #PARPinhibitors #BRCA #MolecularDiagnostics
Apr 2026